For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

PURPOSE: We investigated the number, phenotype, and prognostic significance of CD8+ T cells in patients with mycosis fungoides (MF) and CD30− primary cutaneous large T-cell lymphoma (PCLTCL). PATIENTS ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T ...

Immune checkpoint blockade therapy relies on releasing a natural brake in the immune system to fight cancer. This therapy activates the body’s CD8+ cytotoxic T cells, which mount an attack against ...

Clonally expanded CD8+ T cells are key drivers of alopecia areata, mediating epithelial cell death and immune infiltration. JAK inhibitors are approved for AA treatment, but recurrence is common, ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

Purpose: The permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions is described. Methods: Thirteen cytotoxic agents were prepared at the highest concentrations ...